Bundamedik Healthcare System

What Bundamedik Healthcare System does

Bundamedik Healthcare System (BMHS) is an Indonesian publicly listed healthcare holding company, trading on the Indonesia Stock Exchange under ticker BMHS since its July 6, 2021 IPO. Founded in 1973 in Jakarta by dr. Rizal Sini, Sp.OG as Rumah Sakit Bersalin Bunda, BMHS operates Indonesia's largest maternity hospital group through its RS Bunda Group business unit and runs 9 RSIA/RSU Bunda hospitals across major Indonesian cities including Jakarta, Tangerang Selatan, Bekasi, Depok, Palembang, Surabaya, Padang, and Bali. The company serves individual patients and families with a primary focus on women and children, offering services across eight Centers of Excellence spanning oncology, urology/nephrology, cardiovascular, orthopedics, digestive health, and women's and children's health. Long-standing international partnerships with Queen Elizabeth Hospital and the University of Adelaide date back to 1978, anchoring clinical training and protocol exchange.

The company's core technology stack centers on the Advanced Robotic Minimal Invasive Surgery (ARMIS) program using the da Vinci Surgical System, which BMHS pioneered in Indonesia in 2012 and has since used to perform over 500 procedures across oncology, urology, cardiovascular, orthopedics, digestive, and gynecological specialties. In 2023 the company launched the OneBunda digital platform, a mobile application that unifies appointment booking, health guides, and access to the broader BMHS service ecosystem. The portfolio extends beyond hospital care through subsidiaries including Morula IVF (fertility services, now partnered with Jinxin Fertilities), Diagnos Laboratory (diagnostics, with BMHS holding a 41.20% majority stake), ER Indonesia (emergency response), Visiscan Indonesia (imaging), Bunda Global Pharma, and BMHS Diklat Indonesia (training), as well as the Indonesian Reproductive Science Institute (IRSI).

BMHS generates revenue primarily through usage-based inpatient and outpatient hospital services: consultation fees, diagnostic services, surgical procedures including robotic surgery, inpatient accommodation (priced across five tiers from Rp390,000 to Rp4,560,000 per night), and pharmaceutical sales within its facilities. Pricing is quote-based and not publicly disclosed, with patients routed through the 1500799 call center, the OneBunda app, or direct hospital visits. Go-to-market is a direct-to-consumer hospital sales model with no enterprise B2B contracts disclosed; patient acquisition is supported by social media, health education content, patient testimonials, and a network of specialty centers. Headcount is reported at 101–250, reflecting the corporate/administrative scope, while clinical staff across the hospital network support day-to-day service delivery.

Name

Bundamedik Healthcare System

Legal name

PT Bundamedik

Website

https://bunda.co.id

Company type

Public

Founded year

1973

Operating status

Operating

Headcount range

101–250 employees

Short description

Bundamedik Healthcare System (BMHS) is Indonesia's largest maternity hospital group, operating 9 RSIA/RSU Bunda hospitals across major cities since 1973. The publicly listed holding company delivers specialized women and children's healthcare, pioneered robotic surgery in Indonesia, and integrates diagnostics, IVF, and emergency services through its OneBunda platform.

Ownership category

akta.pro rank

Product category

Hospital Healthcare Services

NAICS

General Medical and Surgical Hospitals (6221), General Medical and Surgical Hospitals (622110), Medical and Diagnostic Laboratories (6215)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Medical Laboratories (8071)

akta.pro primary industry

Critical Access & Rural Hospitals (HLAFAAAG)

Keywords

• Maternity hospital services
• Women's healthcare services
• Fertility treatment services
• Robotic surgery services
• Diagnostic laboratory services

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Offices9 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Hospital Services Revenue: Bundamedik Healthcare System generates revenue primarily through inpatient and outpatient hospital services rendered at its network of hospitals and clinics across Indonesia. Revenue is derived from consultation fees, diagnostic services, surgical procedures, inpatient care, and pharmaceutical sales within its facilities. This is a recurring consumption-based revenue model driven by patient volume across its specialized medical centers.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Bundamedik Healthcare System (BMHS) operates a network of maternity and general hospitals across Indonesia under the RS Bunda Group brand, delivering inpatient and outpatient care, surgical services, maternity and pediatric care, and specialty treatments through Centers of Excellence in oncology, urology, cardiovascular, orthopedics, digestive health, and women's and children's health. The company complements hospital services with fertility treatments (Morula IVF), diagnostic laboratories (Diagnos), pharmaceutical services, emergency response (ER Indonesia), and the OneBunda digital health platform for appointment booking and patient engagement.

Product overview

Bundamedik Healthcare System (BMHS) operates RS Bundametrics Group as Indonesia's largest mother and child hospital network, established in 1973. The ecosystem includes core hospital services (RSIA/RSU Bunda hospitals), digital health platform (OneBunda), fertility services (Morula IVF), diagnostic laboratories (Diagnos), and emergency services (ER Indonesia). The company provides specialized Centers of Excellence including oncology, urology, cardiovascular, orthopedics, digestive, pediatric, and women's health. Advanced capabilities include robotic surgery (ARMIS) pioneered in 2012, with facilities across 9 hospital locations in Indonesia including Jakarta, Padang, Margonda, Palembang, Bandung, Surabaya, and Denpasar. The company went public in 2021 (BMHS stock code) and launched its OneBunda digital platform in 2023.

Differentiator

Problem solved

Functional benefit

Brands

• Morula IVF: Fertility and IVF clinic services under Bundamedik Healthcare System
• ER Indonesia
• Diagnos
• OneBunda
• IRSI

Products and services

• RSIA/RSU Bunda Hospitals Network of maternity (RSIA) and general (RSU) hospitals under the RS Bunda Group brand, providing comprehensive inpatient, outpatient, emergency, and specialized treatment services across nine Indonesian cities including Jakarta, Ciputat, Depok, Bekasi, Palembang, Surabaya, Padang, and Bali.
• OneBunda Digital Health Platform Digital health platform that integrates BMHS hospital services, appointment booking, health guides, and patient engagement into a single mobile application ecosystem.
• Morula IVF Fertility and IVF clinic network providing comprehensive assisted reproduction services to couples and individuals facing infertility, enhanced by a 2024 strategic collaboration with Jinxin Fertilities.
• Diagnos Laboratory Clinical laboratory diagnostic testing services operated through PT Diagnos Laboratorium Utama, providing diagnostic services to hospitals, clinics, and patients across Indonesia.
• ER Indonesia Emergency response and emergency room services network providing 24/7 emergency medical care across BMHS hospital locations in Indonesia.
• Advanced Robotic Minimal Invasive Surgery (ARMIS) Robotic surgery program using the da Vinci Surgical System for minimally invasive procedures across obstetrics/gynecology, urology, digestive, and oncology specialties, with over 500 procedures performed since 2012.
• RSM Oncology Center (Dr. Rizal Sini Memorial Oncology Clinic) Comprehensive cancer care center providing diagnosis, treatment, and management of oncology conditions for cancer patients.
• Uro-Nephrology Center Specialized center for urological and nephrological conditions including kidney care and transplant services for patients with urinary or kidney disorders.
• Cardiovascular Center Heart and cardiovascular disease treatment center providing comprehensive cardiac care services to patients with cardiovascular conditions.
• Bunda Orthopedic Nurturing Experience (BONE) Specialized orthopedic center providing bone, joint, and musculoskeletal treatment and surgical services to patients with orthopedic conditions.
• Digestive Center Gastrointestinal and digestive system specialized care center including endoscopy services for patients with digestive conditions.
• Pediatric Health Center Children's health center providing pediatric care including growth and development monitoring, vaccination, and specialized pediatric services for infants and children.
• Women's Health Center Specialized women's health services including maternity care, gynecology, and reproductive health services for women across age groups.
• Hospital Inpatient Room Accommodations Inpatient accommodation services across five tiers (Bunda Suite/VVIP, Perdana/VIP, Deluxe/Class 1, Superior/Class 2, and Standard/Class 3) with pricing from Rp390,000 to Rp4,560,000, available to admitted patients across RS Bunda Group hospitals.
• Diagnostic Imaging Services Medical imaging services including X-Ray, CT Scan, MRI, Mammography, Ultrasound (2D/3D/4D), and panoramic dental imaging, provided through modern radiology equipment across BMHS hospital facilities.

Quantifiable outcome

• Over 500 robotic surgical procedures performed in Indonesia since 2012

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• Morula IVF Indonesia (Jinxin Fertilities subsidiary)coreStrategic or Co-development Partner · 1 January 2024Bundamedik Healthcare System established a collaboration with Morula IVF Indonesia, a subsidiary of Jinxin Fertilities, in 2024. This partnership strengthens the company's reproductive health and IVF (In-Vitro Fertilization) service capabilities. Jinxin Fertilities is a leading fertility services company, and the Morula IVF brand represents a significant addition to Bundamedik's portfolio of specialized healthcare services.
• Queen Elizabeth HospitalcoreStrategic or Co-development Partner · 1 January 1978Bundamedik Healthcare System established a long-standing collaboration with Queen Elizabeth Hospital since 1978, predating the company's public listing by over four decades. This international hospital partnership has likely contributed to clinical knowledge exchange, medical staff training, and international standard adoption in maternal and specialized healthcare services.
• University of Adelaide, AustraliacoreStrategic or Co-development Partner · 1 January 1978Bundamedik Healthcare System maintains a collaboration with the University of Adelaide, Australia since 1978, representing a long-standing academic medical partnership that has supported clinical excellence, medical education, and knowledge transfer in maternal and specialized healthcare fields.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Others

• Prodia Widyahusada: Prodia is one of Indonesia's largest clinical laboratory networks. It is an adjacent comparable to Bundamedik's Diagnos subsidiary and to the group's diagnostic services strategy, serving similar outpatient and hospital-referred testing demand.
• Diagnos Laboratory (subsidiary, peer-level diagnostic reference): Diagnos is a clinical laboratory in which Bundamedik holds a 41.20% majority stake. As a partially independent diagnostic services operator in Indonesia, it is adjacent to and partly within Bundamedik's ecosystem, providing a reference for Indonesia's lab services competitive set.

Direct peers

• Mayapada Healthcare: Mayapada Healthcare operates a network of general and specialty hospitals in Indonesia. It is a direct peer to Bundamedik as an Indonesian private hospital group pursuing specialty Centers of Excellence and urban expansion.
• Mitra Keluarga Karyasehat: Mitra Keluarga (IDX: MIKA) is a major Indonesian hospital group operating 25+ hospitals, focused on maternity and family healthcare. It directly overlaps with Bundamedik's core maternity and women's health positioning and competes for similar patient segments.
• Rumah Sakit Pondok Indah Group: Pondok Indah Hospital Group is a long-established Indonesian private hospital operator in the Jakarta area. It competes directly with Bundamedik in premium maternity, women's health, and multi-specialty inpatient services.
• Siloam International Hospitals: Siloam is Indonesia's largest private hospital network (IDX: SILO) with 40+ hospitals across the country. It is a direct competitor to Bundamedik in multi-specialty inpatient care, especially in the greater Jakarta region and other major Indonesian cities.

Broad incumbents

• IHH Healthcare: IHH Healthcare is one of the world's largest hospital groups (Mount Elizabeth, Gleneagles, Acibadem, Fortis) with a presence across Asia. It is a broad incumbent comparable to Bundamedik in premium hospital operations and specialty care, though significantly larger and geographically diversified.

Regional players

• Ramsay Sime Darby Health Care: Ramsay Sime Darby operates private hospitals across Malaysia, Indonesia, and Hong Kong. It is a regional peer with a comparable mix of tertiary care hospitals in Indonesia, though with broader geographic diversification than Bundamedik.
• Bangkok Dusit Medical Services (BDMS): BDMS is Thailand's largest private hospital network. While operating in a different country, BDMS is regionally comparable to Bundamedik as a Southeast Asian multi-specialty hospital group pursuing Centers of Excellence and premium patient segments.
• Bumrungrad Hospital: Bumrungrad is a leading Thai-based tertiary care hospital serving domestic and international patients. It is a regional comparable to Bundamedik in terms of specialty care positioning, premium pricing, and reliance on medical tourism within Southeast Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@RumahSakitBunda
• Facebookfacebook.com/rsbundagroup
• Instagraminstagram.com/rsbundagroup
• LinkedInlinkedin.com/company/rs-bunda-grup

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bundamedik Healthcare System